Vivo Opportunity, LLC purchased $392K of INM (indirect holdings)
Vivo Opportunity, LLC purchased 249,227 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.57 ($1.52–$1.69, $0.39M total) across 18 trades over 2026-05-20 to 2026-06-08.
How this was made
The 30-second read
Why it matters
Traders may use the disclosure as a sentiment input, but without accompanying company news it is unlikely to re-rate the stock materially on its own.
Market read
Fresh ownership accumulation in INM is newly disclosed, but the article lacks any new clinical, regulatory, or financing catalyst.
What to watch
The filing shows multiple small trades across a range ($1.52–$1.69), so the market may treat it as incremental accumulation rather than a strong conviction signal.
Background
This is an SEC Form 4 insider transaction: Vivo Opportunity, LLC (10% owner) reports open-market purchases of InMed Pharmaceuticals shares.
Ticker impact
10% owner Vivo Opportunity, LLC bought 249,227 shares of InMed Pharmaceuticals (INM) for ~$391.6K via open-market purchases (Form 4).
Near-term: modest positive bias; follow-through depends on upcoming company-specific catalysts (trials, financing, approvals).
Form 4 is a primary-source ownership change and the buyer is a 10% owner, but the article provides no new operational/clinical/regulatory development—only the transaction details.
Market effects
Limited sector read-through; this is company-specific ownership activity in a small-cap biotech.
None indicated.
None indicated.
Counterpoint
Owner buying can be driven by liquidity/portfolio mechanics or pre-existing plans; the absence of a 10b5-1 plan reduces the ability to infer timing discipline.
Key entities
- issuerInMed Pharmaceuticals Inc.
Subject of the Form 4 insider transaction; ticker INM.
- 10% ownerVivo Opportunity, LLC
Reported open-market purchases totaling ~$391.6K; indirect ownership.
